Open and Closed Loop DTM SCS in Patients With PSPS Type 2: ENDLESS Study
ENDLESS
Open and Closed Loop Differential Target Multiplexed Spinal Cord Stimulation in Patients With Persistent Spinal Pain Syndrome Type II: a European Multicenter Cohort Study (ENDLESS)
1 other identifier
observational
200
1 country
2
Brief Summary
Evaluation of the effectiveness of differential target multiplexed spinal cord stimulation for treatment of Persistent Spinal Pain Syndrome Type II (PSPS-T2). Identification of clinical effective parameters concerning frequency, pulse duration, amplitude and battery consumption/recharge frequency and safety evaluation.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Oct 2025
Typical duration for all trials
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 7, 2024
CompletedStudy Start
First participant enrolled
October 1, 2025
CompletedFirst Posted
Study publicly available on registry
October 7, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
January 1, 2029
October 7, 2025
September 1, 2025
2.3 years
November 7, 2024
September 29, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Overall pain intensity
The primary effectiveness outcome measure is pain intensity measured with the Visual Analogue Scale (VAS), ranging from 0 (no pain) to 100 (maximal pain) in electronic format. Two scales will be presented for low back/neck pain and for leg/arm pain. Ecological momentary Assessment (EMA) will be used to collect pain intensity scores for VAS, whereby pain intensity is measured for multiple times per day for 1 week to reveal patterns of transient or fluctuating symptoms in the environment and context of the patients' lives, without a recall bias.
The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
Secondary Outcomes (20)
Pain intensity for the lower back and leg pain or neck and arm pain component
The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
Medication use
The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
Negative affect
The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
Functional disability
The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
Health related quality of life
The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
- +15 more secondary outcomes
Interventions
Differential target multiplexed stimulation
Eligibility Criteria
Patients with Persistent Spinal Pain Syndrome type 2 (PSPS-T2), who will receive treatment with differential target multiplexed (DTM) SCS.
You may qualify if:
- having chronic pain as a result of PSPS-T2 that exists for at least 6 months with at least moderate pain intensity (4 or higher measured on numeric rating scale (NRS) or 31mm or higher measured on visual analogue scale (VAS) for the dominant pain location.
- being offered treatment with DTM SCS
- being at least 18 years old
You may not qualify if:
- Expected inability of patients to properly operate the SCS system
- History of coagulation disorders, lupus erythematosus, diabetic neuropathy
- Active malignancy
- Addiction to drugs and/or alcohol (more than 5 units /day)
- Evidence of an active disruptive psychiatric disorder or other known condition significant enough to impact perception of pain, compliance to intervention and/or ability to complete questionnaires, as determined by the investigator
- Immune deficiency (e.g. HIV positive, immunosuppressiva)
- Life expectancy \< 1 year
- Local infection or other skin disorder at site of incision
- Pregnancy
- Other implanted active medical device
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
UZ Brussel
Brussels, Belgium
Vitaz
Sint-Niklaas, Belgium
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 7, 2024
First Posted
October 7, 2025
Study Start
October 1, 2025
Primary Completion (Estimated)
January 1, 2028
Study Completion (Estimated)
January 1, 2029
Last Updated
October 7, 2025
Record last verified: 2025-09